Researchers have provided the first evidence of a drug that shows a relatively high response rate for low-grade ovarian cancer patients. In the first-targeted therapy clinical trial for low-grade serous ovarian cancer, eight out of 52 (15 percent) patients had a complete or objective partial response (tumor shrinkage) and 34 (65 percent) had no disease progression during the two-year course of the study. "These are remarkably encouraging results for ...Sunday, 10 February 2013
Drug That Treats Low-grade Ovarian Cancer Developed
Researchers have provided the first evidence of a drug that shows a relatively high response rate for low-grade ovarian cancer patients. In the first-targeted therapy clinical trial for low-grade serous ovarian cancer, eight out of 52 (15 percent) patients had a complete or objective partial response (tumor shrinkage) and 34 (65 percent) had no disease progression during the two-year course of the study. "These are remarkably encouraging results for ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment